FATE Q3 2019 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$142M

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+136.7% YoY

Gross Profit

-$21M-855.2% margin

Operating Income

-$27M-1116.5% margin

Net Income

-$27M-1095.5% margin

EPS (Diluted)

$-0.40

QoQ Revenue Growth

-13.8%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$21M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$340M

Total Liabilities

$72M

Stockholders' Equity

$268M

Cash & Equivalents

$250M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$1M	+136.7%
Gross Profit	-$21M	-$13M	-64.7%
Operating Income	-$27M	-$17M	-62.5%
Net Income	-$27M	-$17M	-58.6%